Table 1. . Biomarkers associated with favorable outcome for sunitinib-treated advanced renal cell carcinoma patients in the Renal EFFECT trial.

Biomarker associated with favorable outcome	p-value
Lower serum Ang-2†	0.0197‡
Higher serum MMP-2†	0.0327‡
Lower tumor HIF-1α§	0.0341

There were no statistically significant associations with efficacy for germline VEGF-A or VEGFR3 single nucleotide polymorphisms assayed or VHL mutation alone, deletion alone, methylation alone or aberrancies combined.

^†Serum soluble proteins identified by both SOMAscan and SearchLight platforms using Response Evaluation Criteria in Solid Tumors-defined response.

^‡SOMAscan platform.

^§Assessed by immunohistochemistry.

Data taken with permission from [3].